Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos Acquires 10,000 Shares

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were bought at an average price of $5.02 per share, for a total transaction of $50,200.00. Following the completion of the transaction, the chief executive officer now directly owns 2,285,731 shares of the company’s stock, valued at $11,474,369.62. This represents a 0.44 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Mihael Hristos Polymeropoulos also recently made the following trade(s):

• On Friday, February 28th, Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock. The stock was bought at an average price of $4.76 per share, with a total value of $47,600.00.
• On Tuesday, February 25th, Mihael Hristos Polymeropoulos purchased 10,000 shares of Vanda Pharmaceuticals stock. The stock was purchased at an average price of $4.46 per share, with a total value of $44,600.00.

Vanda Pharmaceuticals Stock Up 6.7 %

Shares of NASDAQ:VNDA opened at $5.13 on Thursday. The firm has a 50 day moving average of $4.60 and a 200 day moving average of $4.79. The company has a market capitalization of $299.16 million, a price-to-earnings ratio of -16.03 and a beta of 0.74. Vanda Pharmaceuticals Inc. has a 52 week low of $3.71 and a 52 week high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.06. Vanda Pharmaceuticals had a negative return on equity of 3.49% and a negative net margin of 9.51%. The firm had revenue of $53.19 million for the quarter, compared to the consensus estimate of $51.00 million. On average, sell-side analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in VNDA. GSA Capital Partners LLP purchased a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth about $143,000. Empowered Funds LLC boosted its stake in shares of Vanda Pharmaceuticals by 5.3% during the 3rd quarter. Empowered Funds LLC now owns 228,287 shares of the biopharmaceutical company’s stock worth $1,071,000 after acquiring an additional 11,524 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Vanda Pharmaceuticals by 7.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 780,933 shares of the biopharmaceutical company’s stock worth $3,663,000 after acquiring an additional 55,567 shares in the last quarter. Intech Investment Management LLC purchased a new stake in shares of Vanda Pharmaceuticals during the 3rd quarter worth about $84,000. Finally, Massachusetts Financial Services Co. MA acquired a new position in shares of Vanda Pharmaceuticals during the 3rd quarter worth about $864,000. 88.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on VNDA shares. StockNews.com started coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. They issued a “hold” rating for the company. HC Wainwright boosted their price target on Vanda Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, February 18th.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.